Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer
Crossref DOI link: https://doi.org/10.1186/s12906-017-2045-0
Published Online: 2017-12-13
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Thronicke, Anja
Steele, Megan L.
Grah, Christian
Matthes, Burkhard
Schad, Friedemann
Funding for this research was provided by:
Iscador AG Arlesheim, Switzerland
ABNOBA GmbH, Pforzheim, Germany
Helixor GmbH, Rosenfeld, Germany